Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of BMS-986435 in healthy male participants
NCT05686096Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration up to 45 days, Time to maximum observed concentration up to 45 days and 1 more. Started Jan 2023; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05686096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686096.